for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vaccinex Inc

VCNX.OQ

Latest Trade

7.19USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.25

 - 

8.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.19
Open
--
Volume
--
3M AVG Volume
0.12
Today's High
--
Today's Low
--
52 Week High
8.36
52 Week Low
3.25
Shares Out (MIL)
14.86
Market Cap (MIL)
108.65
Forward P/E
-2.72
Dividend (Yield %)
--

Latest Developments

More

Vaccinex Reports Q2 Revenue Of $25,000

Vaccinex Announces $13.8 Million Private Placement

Vaccinex Says Submitted Voluntary Application To Transfer Listing Of Its Common Stock To Nasdaq Capital Market

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vaccinex Inc

Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.

Industry

Biotechnology & Drugs

Contact Info

1895 Mount Hope Ave

+1.585.2712700

http://www.vaccinex.com/

Key Stats

1.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-5.650

2019(E)

-2.690
Price To Earnings (TTM)
--
Price To Sales (TTM)
212.61
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-556.66

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up